Downloading...
Download

MRK

MRK Merck On the Verge of a Breakout? Unusual Calls !!Merck (MRK) is setting up for what could be a high-probability breakout. The stock has been in a falling wedge pattern for several months — a classic technical formation that often precedes sharp upside moves. Price action has now compressed to the end of the wedge, and we may be on the brink of a bullish resolution. 🔍 Technical Setup Falling Wedge Pattern nearing completion Price currently hovering near long-term support ($78.25) Strong bullish divergence forming on momentum indicators (RSI/MACD) The falling wedge is typically a reversal pattern, and given how deep MRK has pulled back from its highs ($134+), the risk/reward here looks compelling. 🔥 Options Flow Today’s options market added fuel to the fire: 48,000 call contracts traded expiring this Friday This sudden surge in short-dated call buying signals aggressive positioning for an imminent move This kind of volume is not retail-driven — it points to potential institutional interest 💡 The Bullish Case With the technical breakout structure in place and strong confirmation from options flow, the case for a bullish reversal is growing. If MRK can close above wedge resistance with volume, it opens the door to a quick move toward $85+, possibly even higher in the coming weeks. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
TRADENATION:MRKLong
by TopgOptions
Merck & Company Potential Post Tariff Resolution Bullish RallyWith potential developments towards the resolution of global tariffs and pharma being defensive in general, MRK price action seems to exhibit signs of a potential Bullish reversal breakout as the price action may form a prominent Higher High with multiple confluences through key Fibonacci and Support levels which presents us with a potential Non-Leverage hold opportunity. Entry: (Buy 1 CMP 76.2 & Buy 2 87.6) Stop Loss: 45 or 0 (depends on trading style as Non-Leverage Buy & Hold is recommended) Potential Range for Targets: 130 - 170
NYSE:MRKLong
by LevelsBySBT
Is MRK Setting Up for a Major Comeback? 🧬Merck & Co. (MRK) is trading around $81.00 down significantly from its 52-week high of $134.63 but this pullback could be your window of opportunity. With a solid forward P/E of 9.02, a 3.9% dividend yield, and a pipeline packed with over 20 potential blockbuster drugs, the fundamentals remain strong despite recent pressure from Gardasil sales in China and looming Keytruda patent concerns. 🎯 Entry Zones: 1) Market price 2) $72.50 (strong historical support) 3) $66 (major accumulation zone) 📈 Profit Targets: TP1: $87 TP2: $99 TP3: $115+ Technically, MRK is still below its 50- and 200-day SMAs, but the PEG ratio of 0.74 suggests it's deeply undervalued relative to its growth potential. A bounce from current levels or deeper supports could kickstart a strong swing toward triple-digit territory — especially if bullish sentiment returns to the healthcare sector. 🔍 Watch for confirmation around support and volume spikes — this setup could become one of the stealth recovery trades of the year. 🛑 Disclaimer: This is not financial advice. Always do your own research or consult a financial advisor before investing.
NYSE:MRKLong
by Robert_V12
MKR Falling Wedge Breakout + Target & Key LevelsBINANCE:MKRUSDT just broke out of a 1-year long falling wedge, see 1D zoom below. Further confirmation would be either: • Daily retest of the resistance as support • Weekly close above the resistance Key Levels to Watch Aside from the demand zone, these are all potential resistances and good candidates for partial TPs. • $520-$720: Key demand zone. A break below it would invalidate any bullish setup. • $1600-$1800: Daily sell order block, and the first resistance to overcome. • ~$2000: 0.382 fib of the move down, and HVN*. • $2300-$2400: 0.5 fib of the move down, daily sell order block and previous support • ~$2800: 0.618 fib of the move down, and HVN*. • $3800-$4000: Daily sell order block, and 2024 high. The falling wedge measured target is $3700 . * HVN = High Volume Node
Long
by AliferCrypto
Undervalued, Oversold, Overlooked: MRK Hits The Key Zone!Hi all, Merck & Co. (MRK) is a global pharmaceutical titan and is currently trading near its 52-week low of ~$79. Anchored by Keytruda’s 7% YoY revenue growth, a stable ~4% dividend yield, and an average fair value estimate of $156.59 (98% upside), MRK appears significantly undervalued. Analysts forecast a 12-month price target of $118.05, implying 49% upside, supported by a strong pipeline and solid financials. While tariff concerns and Keytruda’s 2028 patent expiration pose risks. Technically speaking, MRK has fallen 43% from its all-time high and has reached the strongest area on the chart—a key support zone offering a compelling opportunity to build mid- or long-term positions. This critical area is defined by multiple technical factors, creating a high-probability setup for a potential reversal: Role Reversal Support: A broad, well-established resistance zone, aged like fine wine, has now flipped to act as support. This classic role reversal provides significant confluence to the setup. Textbook Trendline: A perfectly respected trendline, straight out of technical analysis textbooks, has consistently held. The price has approached this trendline from higher highs, underscoring its strength as a key support level. 50% Retracement Level: A critical level often watched for potential reversals. Monthly EMA200 Confluence: The 200-period exponential moving average on the monthly chart adds further strength to this area, reinforcing its technical significance. Strategic Guidance: This setup requires strong conviction. If you’re not prepared to buy in the lower gray areas of this support zone (marked on the chart), do not initiate a position. In today’s market sentiment, your fundamental research must be robust, and technical analysis allows you to get that much confidence to make it happen! Ask yourself: If the price falls further into the gray zones, am I willing to buy more? If your answer is yes, the current price presents a strong entry point for mid- to long-term positions. If the answer is no—if you’re unsure about buying at lower levels or find yourself questioning what to do if prices drop further—refrain from starting a position. In volatile markets, clarity and discipline are essential. Only enter if your strategy is clear and your conviction matches the opportunity! Good luck, Vaido
NYSE:MRKLong
by VaidoVeek
MRK 5M Long Investment Aggressive CounterTrend TradeAggressive CounterTrend Trade - short impulse + exhaustion volume + volumed T1 + volumed 2Sp- + weak test + first bullish bar closed entry Calculated affordable stop limit 1/2 1M take profit Hourly CounterTrend "- short impulse + 1D SOS level" Daily Trend "+ long impulse + SOS level - before 1/2 correction" Monthly CounterTrend "- short impulse + 1/2 correction + exhaustion volume?" Yearly Trend "+ long impulse + 1/2 correction + exhaustion volume?"
NYSE:MRKLong
by MishaSuvorov
MRK Rebound in sight MRK, along with many othe rpharma stocks has taken some serious beating. But we like fear - as an opportunity- and it’s here( I dare say it) based on the bottom most will rejection, aka a shooting star. So here are my forecasts in my crystal ball:: 1. Overall Trend and Structure • Longer-Term Trend: MRK peaked near the $115–$120 region in late 2022/early 2023 and has since been making lower highs and lower lows on the weekly timeframe. This suggests a downward bias over the past 12+ months. • Recent Price Action: Price is hovering around the mid-$80s, testing support in the $80–$83 zone. This area held as support a few times in 2021–2022 and is now being revisited. • Break of Structure (BOS) & Change of Character (CHoCH) Markers: • The chart indicators label potential break-of-structure levels where bulls and bears exchanged control. • Since late 2022, these BOS levels have mostly favored the bears, confirming the downtrend. • A bullish CHoCH would require a strong close and sustained trading above the most recent swing high (somewhere in the $90–$92 zone on the weekly). 2. Key Technical Indicators 1. Stochastic Oscillator (Lower Panel) • Appears oversold or near the lower region. On a weekly timeframe, this sometimes suggests that bearish momentum could be losing steam. A bullish crossover from oversold levels often points to a short-term rebound. 2. Momentum Oscillators (e.g., RSI/MACD, if present) • While not explicitly shown, the lower indicator panel with wave-like patterns suggests momentum has been negative but may be stabilising. 3. Support & Resistance Levels • Immediate Support: $80–$83 zone. A weekly close below $80 could open the door to the mid-$70s or even $70. • Initial Resistance: $90–$92 (recent swing highs). Price needs to reclaim this region to confirm a potential bullish reversal on the weekly timeframe. • Secondary Resistance: $95–$100. If the price clears $92, this would be the next zone of overhead supply from prior consolidation. 3. Possible Scenarios & Probability Estimates Below are hypothetical scenarios with rough probability estimates, assuming no major market-wide shocks and stable macro conditions. Bullish Reversal Scenario (Est. 55–60% probability) 1. Hold Support around $80–$83: • If MRK holds above this region on a weekly closing basis, buyers may attempt a short-term bounce. • Timeframe: Could take 2–5 weeks for a solid weekly close confirming support. 2. Upside Targets: • First Target: $90–$92 (key swing high + psychological level). • Second Target: $95–$100 if price breaks and holds above $92 on strong volume. 3. Catalysts to Watch: • A weekly close above $92 would be a “change of character” from lower highs to a potential new uptrend on the weekly. • Bullish crossover in the Stochastics or MACD on the weekly. Continued Downtrend Scenario (Est. 40–45% probability) 1. Failure at $80 Support: • If the stock breaks below $80 on a weekly close, the downtrend likely continues. • Timeframe: A decisive break can happen within 1–3 weeks if sellers remain strong. 2. Downside Targets: • First Target: $75 region, near previous support levels. • Second Target: $70 if selling pressure accelerates and overall market sentiment remains weak. 3. Catalysts to Watch : • Weak earnings, lowered guidance, or broader market declines. • Stochastics remaining in oversold territory without crossing back up, indicating persistent downward momentum. 4. Trade Direction & Time Estimates • Short-Term (1–4 weeks): • Expect choppy price action around $80–$83. A near-term bounce is possible if momentum indicators turn bullish. • If a bounce materialises, watch $90–$92 as a critical resistance. • Medium-Term (2–3 months): • If bulls successfully defend $80 and break $92, a run to $95–$100 could happen by mid-spring to early summer. • Conversely, if $80 fails, the downtrend may persist into the $70s in a similar timeframe. 5. Risk Management Considerations 1. Confirm Volume & Momentum: • Wait for a weekly close above (or below) key levels ($80 support or $92 resistance) to confirm the trend direction. 2. Position Sizing: • If going long near $80 support, consider a stop-loss just below $80 (e.g., $78–$79) to limit risk. • If anticipating a breakdown, watch for confirmation (weekly close below $80) before entering short positions. 3. News & Fundamentals: • MRK is a large pharmaceutical company sensitive to drug approvals, patent news, and broader healthcare developments. Technicals alone might not capture sudden catalyst-driven moves. Final Thoughts • Most Likely Near-Term Path: A technical rebound attempt from $80–$83, but the stock must decisively clear $90–$92 to signal a genuine bullish reversal on the weekly chart. • Overall Bias: The multi-month trend is still down, so the burden of proof is on bulls to show a structural change in character. Again, these are probabilistic views. Good luck out there
NYSE:MRKLong
by OG_Doge
How To Pick Top Pharma Stocks like a ProAnalyzing the pharmaceutical industry, whose products play a key role in improving the quality of life of people around the world, is quite challenging sometimes also it requires deep knowledge and a careful approach, as I believe that investors should consider many factors, starting with evaluating the efficacy of the analyzed company's medications, including in relation to its competitors and the "gold standards," and ending with an analysis of its financial indicators In this article you will learn how to pick Top Pharma stocks like a pro trader and which factors you should consider, so buckle up 1/ Recognizing the risks At the very beginning, an investor you must recognize that the pharmaceutical industry is highly competitive, where a company's investment attractiveness depends not only on the rate of expansion of its portfolio of product candidates, revenue growth, margins, the amount of total debt and cash on the balance sheet but is also heavily influenced by the expiration of patents on medications and vaccines. Moreover, in recent months, the healthcare sector has increasingly felt the impact of the upcoming 2024 US presidential elections, as some politicians are aiming to further tighten regulation of drug prices despite the existing Inflation Reduction Act. 2/ Leveraging data to your advantage The second step use data wisely, you should check all kinda data including stock screener, transcripts of earnings calls, financial results for the last quarters, analyst expectations, options data... The goal is to filter companies in poor financial condition, as well as those that trade at a significant premium to the sector and/or competitors I would also like to point out that in the current market environment, with Fed interest rates remaining at multi year highs, I do not recommend investing in companies with market caps below $500 million, as they typically have limited cash reserves and weaker institutional backing Also, I'd recommend investors read 10-Ks and 10-Qs, especially the section related to debt and sources of financing of the company's operations, to reduce the likelihood of an "unexpected" drop in the share price. A striking example is Invitae Corporation aka NVTAQ which declared bankruptcy in mid February 2024! Was there a prerequisite for this? The answer is yes since the company continued to generate negative cash flow and also had convertible senior notes maturing in 2028. Convertible notes can involve significant financial risks if the company cannot effectively use the cash to grow the business and break even. In this case, management will not be able to pay off the bonds with cash reserves and will have to resort to significant dilution of investors. In my opinion, Pacific Biosciences of California, Inc. NASDAQ:PACB may face this problem because it has convertible senior notes maturing in 2028 and 2030. Factors that concern me include the company's declining revenue and total cash and short-term investments in recent quarters, while its operating expenses remain extremely high at around $80 million per quarter. Let's return to the second step in my approach to selecting the most promising assets in the healthcare sector. When selecting companies with market caps between $4 billion and $40 billion, I use more parameters since most of them already have FDA approved drugs and/or vaccines. As a result, it is also necessary to consider the rate of growth of operating income, net debt/EBITDA ratio, and how management copes with increased marketing and production costs. Finally, let's move on to the last basket, which contains pharmaceutical companies with market capitalizations exceeding $40 billion. I think, this group is best suited for more conservative investors looking for assets offering attractive dividend yields and growing net income, supported by a rich portfolio of FDA approved and experimental drugs. So, from Big Pharma, I like Pfizer Inc NYSE:PFE , AbbVie Inc NYSE:ABBV , Merck & Co NYSE:MRK and AstraZeneca PLC NASDAQ:AZN . I also want to include Novartis AG NYSE:NVS and Roche Holding AG OTC:RHHBY in this group sometimes investors need to make exceptions, namely if one larger company buys out a smaller player and/or when a major partnership agreement is concluded, as was the case between Merck and Daiichi Sankyo Company, Limited OTC:DSKYF in 2023. Also, in the event of a major acquisition or merger, the company's debt may temporarily increase sharply. If its management has previously implemented effective R&D and financial policies, the "net debt/EBITDA ratio" A remarkable example of a company falling into the "value trap" is Takeda Pharmaceutical Company Limited NYSE:TAK , which overpaid for Shire. This deal did not significantly strengthen or rejuvenate the Japanese company's portfolio of drugs. As a result, it had to sell off billions of dollars in assets to pay off its debt partially. However, despite all the efforts of Takeda's management, its net debt/EBITDA ratio, although it fell below 5x, remains high, namely about 4.7x at the end of March 2024. 3/ Identifying promising therapeutic areas In general, the more prevalent a disease is, the larger the total addressable market for a drug and, as a result, the higher the chances that it will become a commercially successful product. Global spending on cancer medications will reach $377 billion by 2027, followed by immunology, and diabetes will come in third with an estimated spending of about $169 billion What challenges arise when choosing pharmaceutical companies? you should also keep in mind that the larger the market, the higher the competition between medicines, as companies strive to grab as big a piece of the pie as possible. As a result, for drug sales to take off, they need to have significant competitive advantages over the "gold standard." These competitive advantages may include greater efficacy in treating a particular disease, less frequent administration, a more favorable safety profile, and a more convenient route of administration. So, in recent years, competition in the global spinal muscular atrophy treatment market has intensified. Spinal muscular atrophy is a genetic condition. Currently, three drugs have been approved to combat the disorder, including Biogen Inc.'s (BIIB) Spinraza, Roche/PTC Therapeutics, Inc.'s (PTCT) Evrysdi, and Novartis AG's (NVS) gene therapy Zolgensma. All three products have similar efficacy, but Evrysdi has a more favorable safety profile and is the more convenient route of administration, namely the oral route, which is reflected in its sales growth rate from year to year. The second pitfall is the company's pipeline of experimental drugs. I believe that financial market participants opening an investor presentation that presents a company's pipeline, especially if its market cap is below $5 billion, should also pay close attention to what stage of clinical trial activity its experimental drugs are in. if a pharmaceutical company has most of its product candidates in the early stages of development, this represents a significant risk because, in this case, institutional and retail investors are often overly optimistic about the prospects for the drugs' mechanisms of action and/or clinical data obtained in a small group of patients. Simultaneously, as is often the case, the higher the optimism, the less favorable the risk/reward profile. In most cases, the larger and more diverse the patient population, the weaker the efficacy of a drug relative to what was seen in Phase 1/2 clinical trials. This ultimately leads to a downward valuation of its likelihood of approval and casts doubt on its ability to take significant market share from approved medications. This may subsequently reduce the company's investment attractiveness, making it more difficult to attract financing for its operating activities. As a result, I recommend excluding any company that, instead of focusing its financial resources on the most promising product candidates, conducts multiple early-stage clinical trials to evaluate the efficacy of its experimental drugs. In my experience, the most successful pharmaceutical companies focus their efforts on bringing up to three product candidates to market and then reinvesting the revenue from their commercialization into developing the rest of the pipeline. The table below highlights the following parameters that I use to screen out the least promising companies. A third factor that investors, especially those new to the investment world, should consider is that large pharmaceutical companies are leaders in certain therapeutic areas, with a rich portfolio of patents covering various mechanisms of action and delivery methods of drugs, making it more difficult and more prolonged for smaller players to find product candidates that could potentially have the competitive advantages. So, Novo Nordisk A/S NYSE:NVO and Eli Lilly and Company NYSE:LLY have long been leaders in the global diabetes and weight loss drugs markets, and only very recently, they may be joined by Amgen Inc. NASDAQ:AMGN , Roche Holding, and several other companies 4/ Assessing a company's drug portfolio in comparison to competitors Evaluating the effectiveness, safety profile, and mechanism of action of a medication, as well as comparing clinical data with its competitors, takes a lot of time and effort. I provided examples of drugs and the most promising mechanisms of action in the obesity treatment market. Their manufacturers are Eli Lilly, Novo Nordisk, Roche Holding, Viking Therapeutics, Inc, Amgen, Pfizer, Altimmune, Inc, OPKO Health, Inc, Boehringer Ingelheim, and Zealand Pharma A/S 5/ When market exclusivity for a company's key medications ends Every financial market participant who is considering investing in pharmaceutical companies should consider the expiration time of key patents of medicines. Marketing exclusivity represents protection against the entry of a generic version and/or biosimilar of a branded drug into the market, thereby allowing the company to recoup the resources spent on its development and, in the event of its commercial success, also reinvest the money received to accelerate the development of the remaining product candidates. Where can you find information about patent expiration dates? All the necessary information is either in 20-Fs/10-Ks or on the FDA website, namely in the "Orange Book" section. let's take Eli Lilly as an example. Open the latest 10-K. Then, the CTRL + F combination opens the ability to find specific words in the document. I usually enter "Expiry Date" or "compound patent" to find the patent section.nvestors can also find information about patents on the FDA website. As an example, I enter "Mounjaro" in the top line, and a list of patents opens that protect Eli Lilly's blockbuster from the introduction of its generic versions onto the market.hen, clicking on "Appl. No." will open information about the submission date of the patent and when it will expire. 6/ Evaluating the impact of insider share transactions The next step in selecting the most interesting assets in the healthcare sector is to analyze Form-4s. The CEO, CFO, and other key members of the company's management buy or sell shares from time to time.I am only interested in analyzing purchases since, most often, sales by management are option exercises carried out to pay taxes. When management starts making large outright purchases of a company's shares, it can signal that it believes in its long-term growth potential.if more than two top managers buy a large block of shares within two weeks of each other, it significantly increases the likelihood of the company's stock price rising in the next two months from the moment of their transactions But as with everything, there are exceptions, such as in the case of OPKO Health, which is developing a long-acting oxyntomodulin analog for the treatment of obesity together with LeaderMed Group.Over the past 12 months, OPKO's management, especially CEO Phillip Frost, has purchased over 12 million shares. However, despite this, its stock price has fallen by 27% over the same period. I believe that the key reasons for the divergence between these two facts are investors' lack of confidence in Phillip Frost's ability to make the company profitable again, as well as its low cash reserves. Therefore, companies like OPKO Health have already been eliminated at the second step of selection using Seeking Alpha's screener. 7/ CEO Performance in Business Development The CEO plays a crucial role in the success of a pharmaceutical company since the pharmaceutical industry is highly dynamic, and the competition between Big Pharma is especially high, I advise readers to pay attention to the track record of the CEO, especially how he copes with force majeure situations, as well as how effective the R&D policy is carried out under his leadership. 8/ Identifying Entry and Exit Points for Long-Term Investments The eighth step is in addition to the information that was obtained in the previous steps, as well as the analysis of financial risks and various financial metrics of the company, including its net debt, maturity dates of bonds, historical revenue growth rates, EBIT, gross margin, I build a DCF model with the ultimate goal of determining the price target. it is necessary to conduct a technical analysis of them, as well as the main ETFs that include them. In my opinion, the key ETFs are the SPDR® S&P Biotech ETF AMEX:XBI , Fidelity Blue Chip Growth ETF AMEX:FBCG , iShares Biotechnology ETF NASDAQ:IBB , and VanEck Pharmaceutical ETF $PPH. The purpose of technical analysis is to determine the stop-loss level and entry points at which the risk/reward profile is most favorable. taking profit is not that easy cuz you must master your emotions and greed which damn hard 9/ Creating a Watchlist Based on Risk/Reward Ratio The purpose of which is to create a watchlist of the companies I have selected based on the previous steps. I make several lists of companies based on their market caps and also rank them according to risk/reward profile, that is, in the first place is the stock that I think has minimal risks and at the same time can bring the greatest potential profit. I also advise creating small notes on each company, which can include information about risks, support/resistance zones, dates of publication of clinical data, and any thoughts you have that will make your decision more conscious when opening a position “What’s your secret sauce for choosing pharma stocks?”
NYSE:NVOEducation
by moonypto
Despite Beating Q2 Expectations Merck Stock Slides KEY TAKEAWAYS: - Merck & Co. revised its full-year adjusted EPS projection to $7.94-$8.04, down from $8.53-$8.65. - Second-quarter sales of its flagship drug, Keytruda, rose 16% year-over-year. - The company beat Q2 expectations on both revenue and profit metrics. Shares of Merck & Co. ( NYSE:MRK ) plummeted on Tuesday after the pharmaceutical giant slashed its full-year adjusted profit guidance. Despite delivering solid second-quarter earnings and revenue, the outlook revision overshadowed the company’s performance, causing a significant dip in its stock price. Earnings and Revenue Beat Expectations In the second quarter, Merck reported earnings per share (EPS) of $2.14 on revenue of $16.11 billion, surpassing analysts' expectations of $2.05 EPS and $15.88 billion in revenue, as per Visible Alpha. The company’s pharmaceutical division contributed $14.41 billion to the revenue, marking a 7% increase from the previous year. Merck’s flagship cancer drug, Keytruda, was a standout performer with sales surging 16% to $7.27 billion. Another notable contribution came from Winrevair, a pulmonary arterial hypertension drug approved by the FDA in March, which generated $70 million in sales. Guidance Cut and Stock Reaction Despite the strong quarterly performance, Merck lowered its full-year adjusted EPS guidance to a range of $7.94-$8.04, down from the prior range of $8.53-$8.65. This adjustment reflects the impact of a one-time charge of approximately $1.3 billion, or $0.51 per share, related to the acquisition of EyeBio. The market reacted sharply to this news, with Merck's shares dropping over 9% to $115.91 by late morning on Tuesday. The stock experienced its most significant loss in three years, falling as much as 7.7%, largely due to concerns over the reduced profit outlook and issues with Gardasil shipments in China. Challenges and Strategic Moves Merck’s reduced profit forecast was partly influenced by lower-than-expected sales of its Gardasil HPV vaccine in China. Chief Executive Officer Rob Davis highlighted a “surprising” decrease in Gardasil shipments to China due to issues with a third-party distributor. This unexpected downturn in one of the world’s most populous markets raised concerns about the long-term sales targets for Gardasil. Merck ( NYSE:MRK ) has been proactive in seeking new growth avenues as its blockbuster drug Keytruda faces future pricing pressures. Last year, Merck spent nearly $11 billion to acquire Prometheus Biosciences Inc., a maker of treatments for autoimmune disorders. Additionally, Merck entered a deal with Daiichi Sankyo Co. worth up to $22 billion to collaborate on novel cancer medicines. Updated Revenue Forecast and Future Prospects Despite the lowered EPS guidance, Merck increased its full-year revenue forecast by $200 million at the median, to a range of $63.4 billion to $64.4 billion. The company’s next significant product, Winrevair, has shown promise, bringing in $70 million in its first full quarter on the U.S. market, exceeding analysts' expectations. Adjusted earnings for Q2 were $2.28 per share, beating analysts’ average estimate by 11 cents. Revenue also outperformed expectations, bolstered by a 16% increase in Keytruda sales. BMO analyst Evan Seigerman remarked on Merck’s consistent commercial performance, noting that the Winrevair launch exceeded even the highest expectations. He stated, “Another quarter of the same story. Merck commercial outperformance remains steady.” Technical Outlook As of the present time, the stock of Merck ( NYSE:MRK ) has experienced a considerable decline of 9.45%. The Relative Strength Index (RSI) is currently at 30.09, indicating the stock is approaching the oversold region. Furthermore, a detailed inspection of the daily price chart reveals the presence of a long bearish Harami candlestick pattern, which is widely recognized as a significant reversal pattern in technical analysis. Conclusion Merck’s stock slide following the guidance cut underscores the market’s sensitivity to profit projections, even in the face of strong quarterly results. The company’s robust performance in Q2, driven by Keytruda and the successful launch of Winrevair, demonstrates Merck’s potential for growth despite current challenges. However, the reduced profit outlook and issues with Gardasil shipments in China highlight the hurdles Merck must navigate to maintain its market position and investor confidence.
NYSE:MRKShort
by DEXWireNews
Merck's Keytruda Triumphs in Q4 Reports Merck & Co ( NYSE:MRK ) has emerged victorious in its fourth-quarter performance, exceeding market expectations fueled by the remarkable success of its flagship cancer immunotherapy drug, Keytruda. The pharmaceutical giant reported robust financials, driven by a 21% surge in Keytruda sales, catapulting it to the status of the world's best-selling prescription medicine. This stellar performance not only defied analyst predictions but also positioned Merck ( NYSE:MRK ) as a frontrunner in the pharmaceutical industry. Keytruda's Stellar Performance: Keytruda's sales reached an impressive $6.6 billion in Q4, outpacing estimates and contributing to a total annual revenue of $25 billion. The drug's success is attributed to Merck's strategic efforts to expand its usage in earlier stage cancers. Despite its impending patent expiration by the end of the decade, Keytruda remains a formidable asset for Merck ( NYSE:MRK ), overshadowing even the peak sales of AbbVie's blockbuster arthritis drug, Humira. Strategic Moves to Counter Patent Exclusivity Loss: Aware of the looming patent exclusivity loss, Merck ( NYSE:MRK ) has proactively engaged in strategic initiatives to mitigate the impact. The pharmaceutical giant recently entered into multiple deals, including a significant $5.5 billion collaboration with Japan's Daiichi Sankyo for the co-development of three promising cancer drugs. These moves signify Merck's commitment to maintaining its competitive edge and market leadership in the evolving pharmaceutical landscape. Optimistic Outlook and Pipeline Expansion: Merck ( NYSE:MRK ) has revised its outlook for the mid-2030s, projecting adjusted annual sales for new oncology products to exceed $20 billion, up from the initial estimate of over $10 billion. The company has similarly elevated its mid-2030s forecast for cardiometabolic products to approximately $15 billion, demonstrating confidence in the potential of its diversified portfolio. Financial Resilience and Restructuring Efforts: Despite taking a charge of $1.69 a share related to the Daiichi deal, Merck ( NYSE:MRK ) reported adjusted earnings of 3 cents per share in Q4, defying expectations of an 11 cents per share loss. The company's Q4 revenue of $14.6 billion, a 6% increase from estimates, further underscores its financial resilience. Merck has also initiated a restructuring program aimed at optimizing manufacturing operations for both human and animal health, projecting completion by the end of 2031. While this program incurs approximately $4 billion in cumulative pre-tax costs, Merck's proactive stance signals a commitment to long-term operational efficiency. Conclusion: Merck's ( NYSE:MRK ) stellar Q4 results, fueled by Keytruda's exceptional sales performance and strategic initiatives, position the company for a decade of resilience in the face of impending challenges. The pharmaceutical giant's optimistic outlook, robust financials, and proactive measures to address patent exclusivity loss underscore its commitment to innovation, strategic partnerships, and sustained growth.
NYSE:MRKLong
by DEXWireNews
The Healthcare Sector Index $XLV - Worth Watching SPDR Select Sector Fund – Healthcare Index AMEX:XLV The chart speaks for itself, we have our breakout levels and our break down levels. We enter on a breakout and set a stop 5% under that support and we exit and or short if we fall under the two underside support levels. Below I outline some reasons why the healthcare sector is worth paying attention too. The healthcare industry is worth $808 billion in the United States as of 2021. 65% of the industry’s revenue comes from patient care. The global healthcare industry is worth $12 trillion. In the U.S National health expenditures are projected to grow 5.4 percent, on average, over the course of 2023–31 and to account for roughly 20 percent of the economy by the end of that period. The insured share of the population is anticipated to exceed 92 percent through 2023 (figures pending), in part as a result of record-high Medicaid enrolment, and then decline toward 90 percent as coverage requirements related to the COVID-19 public health emergency expire. The growth of the health-care sector is evident in employment data as well. In 1990, about 8 million Americans worked in health care; that figure has since doubled to 16 million. That’s the largest single employment segment in our economy. In addition to the above, the west in general is an aging populace that is living longer. We will need these services more than we need staples during a recession. I believe this index can help us gauge the healthcare sector and what direction it will go next. We can watch the levels outlines and make a play if we wish. We have a hard upper boundary and lower boundary on a parallel channel on the chart. You know what to do when we breach any of these levels. Outlined on the chart XLV fund provides exposure to companies in pharmaceuticals, health care equipment and supplies, health care providers and services, biotechnology, life sciences tools and services, and health care technology industries. XLV is the oldest in the segment, as such it is used widely for strategic or tactical positions. Since XLV is both cap weighted and fishes only from the S&P 500, it tilts heavily toward mega-caps. For focused exposure to leading health care names, XLV is tough to beat. Top Five Holdings UnitedHealth Group Inc NYSE:UNH 9.63% Eli Lilly and Co NYSE:LLY 9.19% Johnson & Johnson NYSE:JNJ 7.46% Merck & Co NYSE:MRK 5.46% AbbVie Inc 5.41% Stay Healthy and Nimble Folks PUKA
AMEX:XLV
by PukaCharts
Merck to Acquire Harpoon Therapeutics in $680M DealNavigating the Oncology Frontier with Harpoon Therapeutics Acquisition In a significant strategic move, pharmaceutical giant Merck & Co. ( NYSE:MRK ) has announced its plans to acquire cancer drugmaker Harpoon Therapeutics Inc. ( NASDAQ:HARP ) in a transformative deal valued at $680 million. The move aims to solidify Merck's leadership position in the highly lucrative oncology space, diversifying its portfolio and positioning itself for sustained growth in the face of potential challenges for its flagship cancer immunotherapy, Keytruda. The Deal Overview: Merck's acquisition of Harpoon Therapeutics involves a payment of $23 per share, more than double Harpoon's last closing share price, signaling Merck's strong commitment to the strategic partnership. The deal is currently pending, awaiting approval from Harpoon shareholders, with the expected closure in the first half of 2024. Keytruda and Beyond: Merck's pursuit of Harpoon Therapeutics aligns with its broader strategy of seeking new sources of growth. With Keytruda generating a substantial $20.9 billion in 2022, Merck recognizes the importance of expanding its pipeline to maintain a competitive edge. Harpoon's promising early-stage trials and T-cell engager assets present Merck with an opportunity to diversify its oncology offerings and explore new avenues of therapeutic innovation. Analyst Insights: Merck's acquisition of Harpoon is a strategic and value-driven move. The early but promising data from Harpoon's T-cell engager assets, coupled with investor interest in similar technologies, positions Merck for potential growth in the oncology market. Building a Robust Portfolio: Merck's proactive approach to portfolio expansion is evident in its recent deals, including the acquisition of Daiichi Sankyo Co.'s experimental cancer drugs and the purchase of autoimmune drugmaker Prometheus. These moves showcase Merck's commitment to staying at the forefront of medical innovation and bolstering its position in key therapeutic areas. Investor Sentiment and Momentum: As evidenced by the stock's current trading position near the top of its 52-week range and above its 200-day simple moving average, investor sentiment towards Merck is positive. Conclusion: Merck's acquisition of Harpoon Therapeutics marks a pivotal moment in the pharmaceutical landscape, where innovation and strategic partnerships are crucial for sustained growth. By expanding its oncology portfolio with cutting-edge technologies, Merck positions itself as a leader in the fight against cancer, ensuring a robust pipeline and securing its role as a key player in the evolving healthcare landscape. As the deal progresses towards closure, investors and industry observers will keenly watch Merck's journey into a new era of therapeutic possibilities.
NYSE:MRKLong
by DEXWireNews
1